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Abstract: Background: Angiotensin Converting Enzyme inhibitors (ACEis) and beta-blockers (BB)
are suggested to prevent and treat trastuzumab-related cardiac toxicity. We performed a prospective
clinical trial in women experiencing mild cardiac toxicity (MCT) while on adjuvant treatment with
trastuzumab. Methods: MCT was defined as an asymptomatic absolute decrease in LVEF of ≥ 10
percentage units to >50%. Treatment consisted of enalapril 2.5 mg bid and carvedilol 3.75 mg bid,
which were up-titrated to 10 mg bid for the enalapril and 6.25 mg bid of carvedilol. In patients
receiving study drug, the primary study end-point was LVEF recovery, which was defined as a
post-trastuzumab LVEF returning to no less than −5 percentage points of the baseline value. Results:
103 patients were enrolled, 100 started trastuzumab, and 98 completed the planned treatment. Sixteen
patients (16%) had MCT and received study drugs until trastuzumab completion. None of these
patients achieved a post-trastuzumab LVEF recovery. Nevertheless, treated patients had significantly
higher median LVEF recovery from nadir to post-trastuzumab LVEF in (8% points vs. 4% points,
respectively, p = 0.004), resulting in no difference in post-treatment LVEF values compared to patients
without MCT. Conclusion: Treatment of MCT with ACEis and BB allows faster LVEF recovery from
nadir values and should be further studied in this setting.
Keywords: breast cancer; trastuzumab; cardiac toxicity; enalapril; carvedilol; ACE inhibitors;
beta blockers
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1. Introduction
Amplification or overexpression of the human epidermal growth factor receptor 2 (HER2) oncogene
characterizes approximately 15–20% of patients with breast cancers (BC) and is associated with early
disease progression and poor prognosis [1,2].
Trastuzumab, a recombinant humanized monoclonal antibody that binds the extracellular domain
of HER2, improves overall survival (OS) and disease-free survival (DFS) in patients with early, HER2
positive operable breast cancer [3].
Although trastuzumab is generally well tolerated, cardiac dysfunction is a significant adverse effect,
especially in patients with prior or concomitant exposure to anthracycline-based chemotherapy [4].
In a recent pooled analysis of three pivotal randomized clinical trials, 11.3% of the women in the
trastuzumab arms experienced a cardiac event, which was mildly symptomatic or asymptomatic
for the majority of them (8.7%) [5]. Severe congestive heart failure occurred in 2.8% of the patients
receiving trastuzumab.
Trastuzumab-related cardiac toxicity may lead to definitive interruption of trastuzumab and
long-term cardiac sequelae. For this reason, especially in the early breast cancer setting, guidelines on
how to treat cardiac dysfunction during treatment have been widely adopted [4]. Practically, while
symptomatic cardiac toxicity mandates trastuzumab interruption and appropriate cardiac therapy,
thresholds have been identified in asymptomatic patients experiencing left-ventricular ejection fraction
losses compared to pre-treatment values to trigger temporary interruption and cardiac treatments.
Clinical studies have addressed strategies to predict, prevent, and treat clinically significant,
trastuzumab-related cardiac toxicity [6]. Cardiac markers, such as high sensitive troponin I (hs-TnI)
and N-Terminal Prohormone of Brain Natriuretic Peptide (NT-ProBNP), are sensitive and specific
markers to detect myocardial injury, to predict treatment-related decreases in left ventricular ejection
fraction (LVEF) and the development of left ventricular dysfunction and heart failure [7]. Based on the
physiopathology of trastuzumab-related cardiac toxicity, angiotensin-converting enzyme inhibitors
(ACEis) and beta-blockers (BB) are widely recommended as initial treatment of heart failure and for
clinically significant trastuzumab–related cardiac dysfunction because of their demonstrated ability to
attenuate or reverse left ventricular remodelling [6–8].
Loss of LVEF percentage points not requiring specific intervention (i.e., not fulfilling the criteria for
trastuzumab interruption), occurs but is largely underreported in the clinical practice. Currently, it is not
fully understood whether this “mild” cardiac toxicity (MCT) has immediate or late consequences. We,
therefore, decided to conduct a prospective trial evaluating the potential role of early pharmacological
intervention with ACEis and BB in patients with operable, HER2 positive breast cancer who, during
trastuzumab treatment, developed LVEF loss not requiring trastuzumab discontinuation.
2. Results
2.1. Patient Disposition
A total of 103 women with HER2-positive localized breast cancer signed informed consent
and entered the study. Table 1 shows the demographics of the enrolled patients, and Figure S1
(Supplementary Materials) shows the protocol flow.
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Table 1. Baseline demographics and tumor characteristics for the study population.
Characteristics No. (%)
Median age, years (range) 53 (33–82)
Median BMI (range) 24 (17–38)
Smoking history
Never 68 (66)
Past 6 (6)
Current 19 (18)
Not Know 9 (9)
Chronic Alcohol Exposure 5 (5)
Cardiovascular risk profile
Hypertension 13 (13)
Type II diabetes 1 (1)
Dyslipidemia 3 (3)
Hypothyroidism 5 (5)
Hyperthyroidism 1 (1)
Stage
I 48 (47)
II 36 (35)
III 18 (17)
Histologic subtype
Ductal/NST 94 (91)
Lobular 6 (6)
Papillary 2 (2)
Others 1 (1)
Estrogen and/or progesterone receptor positive 77 (75)
HER2 status by IHC
HER3+ 74 (72)
HER2+/FISH positive 29 (28)
Anthracycline use in neoadjuvant or adjuvant CHT 85 (82)
Taxane use in neoadjuvant or adjuvant CHT 103 (100)
Trastuzumab administration
Concurrent with a non-anthracycline regimen 18 (17)
Sequential, after anthracycline regimen 81 (79)
Only trastuzumab (for patient decision) 1 (1)
Did not start trastuzumab 3 (3)
Concomitant RT 59 (57)
RT on the left chest wall 30 (29)
Pre-treatment LVEF, median % (range %) 67 (57–76)
Pre-treatment BNP, median (range), pg/mL 33 (0–147)
Pre-treatment TnI, median (range), ng/mL 0.01 (0.001–0.100)
BMI: body mass index, NST: no special type, CHT: chemotherapy, RT: radiotherapy, LVEF: left ventricular ejection
fraction, BNP: B-type Natriuretic peptide, TnI: troponin I.
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One patient who had signed the informed consent was found to have stage IV during the
subsequent diagnostic workup and was excluded from subsequent analyses. Of 102 patients starting
adjuvant treatment, one developed metastatic disease upon the completion of anthracycline-based
chemotherapy. We recorded the pre-trastuzumab LVEF value, but this patient, who started
chemotherapy plus trastuzumab and pertuzumab as routine first-line treatment for advanced
breast cancer, was excluded from subsequent analyses. Another patient, upon the completion
of anthracycline-based therapy, decided to continue treatment at another Institution and dropped off
protocol. Of a total of 100 patients eligible for trastuzumab, 98 had a pre-trastuzumab LVEF assessment
performed in the protocol-defined time-window, whereas two who had received anthracycline-based
therapy, had a pre-trastuzumab LVEF performed after the initiation of trastuzumab-based therapy.
These patients will be included in the intent-to-treat analyses. Eighty-one patients started trastuzumab
with taxanes after 3 or 4 cycles of anthracycline (either FEC100 X3 or EC90 X4) and are defined as “group
1”. The other 19 patients did not receive anthracycline before trastuzumab and are defined as “group
2”. Ninety-eight of the patients (98%) were able to complete the planned intended treatment with
trastuzumab (median duration 52 weeks, range 14–76). For one patient, trastuzumab was stopped
after 14 weeks because of cardiac side effects. Another patient stopped trastuzumab after 18 weeks
because of personal choices, in the absence of any toxicity.
2.2. Cardiac Monitoring by Ultrasonography
A total of 719 LVEF evaluations were performed during the study (Figures S2 and S3,
Supplementary Materials). Table S1 (Supplementary Materials) and Figure 1 provide summary
statistics of the overall LVEF findings of our study at the baseline, nadir (lowest LVEF registered during
the study) and after treatment (from 3 to 12 months after the last dose of trastuzumab).
Figure 1. Summary of LVEF findings at baseline, LVEF nadir, and post-treatment according to prior
exposure to anthracycline. The box extends from the 25th to the 75th percentile. The line is the median
LVEF value. The lines extend to the largest and smallest observed values within 1.5 box lengths; “o”
symbols represent outliers (values between 1.5 to 3 box lengths from the upper or lower edge of the
box), asterisks represent extreme values (values of more than 3 box lengths from the upper or lower
edge of the box).
Notably, before trastuzumab, group 1 patients had significantly lower values than group 2 patients
(p = 0.048). Nadir values were significantly lower to both baseline and pre-trastuzumab values
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overall and separately for group 1 and 2 patients. While not different between group 1 and 2 patients,
post-trastuzumab values were significantly lower compared to baseline values.
2.3. Cardiac Events
Nineteen patients were referred to our cardiologist during the study. For 3 of them, the reasons
were not related to LVEF findings (palpitations, shortness of breath, and EKG abnormalities), and
trastuzumab was continued and completed as planned. The other 16 patients (15 in group 1 and
1 in group 2) developed mild cardiac toxicity (MCT) and were started on study drugs (16%, 95%
C.I. 9–25%). These were well tolerated during the up-titration phase, with no patien discontinuing
treatment because of intolerance. One of these patients developed further LVEF loss to less than 40%,
became symptomatic and stopped trastuzumab treatment. The remaining 15 patients were able to
complete trastuzumab without treatment withholdings or delay. Except for the patient developing
symptomatic LVEF loss, for no patient LVEF value dropped below 50% during treatment (Figures
S2 and S3, Supplementary Materials). Figure 2 shows the Kaplan Meyer curve of time to the first
presentation in the 16 patients who experienced MCT.
Figure 2. Kaplan-Meier curve of time to the development of mild cardiac toxicity (MCT).
The median time-to MCT was 26 weeks from the initiation of adjuvant therapy (95% C.I. 13–37
weeks). Table S2 (Supplementary Materials) and Figure 3 provide summary statistics of the LVEF
findings in patients developing and not developing MCT.
Baseline and pre-trastuzumab LVEF values between patients with or without MCT were not
statistically significantly different. As expected, the difference in nadir LVEF between patients with
and without the MCT was highly statistically significant. Interestingly, post-trastuzumab LVEF values
were not statistically significantly different between patients with and without MCT. Indeed, patients
who experienced MCT and, therefore, received study drugs had a significantly higher median LVEF
recovery from nadir to post-trastuzumab LVEF than patients who did not develop MCT (8% points vs.
4% points, respectively, p = 0.004).
No patient developing MCT recovered, after trastuzumab completion, to an LVEF no less than −5
percentage points of the baseline value (primary study endpoint). Conversely, a recovery from nadir
occurred in 48% of patients with did not develop MCT (p < 0.001). As a result, post-trastuzumab LVEF
values were lower than baseline and pre-trastuzumab values.
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Figure 3. Summary of LVEF findings at baseline, LVEF nadir and post-treatment according to the
occurrence of the cardiac event of interest. The box extends from the 25th to the 75th percentile. The
line is the median LVEF value. The lines extend to the largest and smallest observed values within 1.5
box lengths; “o” symbols represent outliers (values between 1.5 to 3 box lengths from the upper or
lower edge of the box), asterisks represent extreme values (values of more than 3 box lengths from the
upper or lower edge of the box).
2.4. Potential Predictors of MCT
Table 2 shows the univariate analysis of potential predictors of MCT. Age, baseline LVEF, Body Mass
Index (BMI), baseline TN I and BNP values were studied both as continuous and dichotomous variables.
Table 2. Univariate analysis of predictors of MCT.
Variable OR P 95% C.I.
Age (≥54) 0.586 0.587 0.253–2.176
Baseline LVEF ≥67 0.550 0.305 0.176–1.722
Left Sided RT 0.487 0.292 0.128–1.854
RT 1.250 0.691 0.416–3.757
Current or former smoker 2.143 0.513 0.218–21.047
BMI >25 0.777 0.666 0.247–2.445
Family History of CVD 3.161 0.042 1.044–9.568
Hypertension 2.778 0.131 0.738–10.642
Prior Anthracycline 4.091 0.187 0.506–33.083
Baseline TnI >0.01 1.588 0.417 0.519–4.857
Baseline BNP >33 0.886 0.827 0.299–2.620
LVEF, left ventricular ejection fraction; RT, radiation therapy; BMI, body mass index; CVD, cardiovascular disease;
TnI, troponin I; BNP, b-type natriuretic peptide.
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Continuous variables were dichotomized around their median values. Although there were trends
for smoking, hypertension, and receipt of anthracycline, only a family history of cardiovascular disease
(CVD) was significantly associated with a three-fold increase in the risk of MCT. Various multivariable
models were studied using all the potential predictors, regardless of their significance at univariate
analysis, yet a family history of CVD remained the only significant predictor.
3. Discussion
In our study, we found a 1% incidence of symptomatic cardiac toxicity leading to treatment
discontinuation and a 98% trastuzumab completion rate with no treatment delays due to cardiac
events. LVEF values declined substantially and, despite recovery in most patients, post-treatment
values were significantly lower compared to baseline. No patient experiencing MCT achieved an
LVEF recovery to no less than −5 percentage point of the baseline value, which was the primary study
endpoint. Nevertheless, the magnitude of recovery from nadir values was significantly higher in
patients receiving study drugs. Therefore, despite lower LVEF nadir values, post-trastuzumab LVEF
values did not differ significantly between patients experiencing and not experiencing MCT, suggesting
a potential role for early medical intervention targeted on asymptomatic LVEF loss. Univariate analysis
showed that only a family history of cardiovascular disease was associated with an increased risk
of MCT, although strong trends not reaching statistical significance were seen for having received
anthracycline before trastuzumab and for a positive personal history of smoking. These results provide
a rationale for de-escalating strategies and a randomized study of early targeted pharmacological
intervention in women receiving trastuzumab-based adjuvant therapy for breast cancer.
Based on the OHERA trial, the largest, prospective, observational study of cardiac toxicity in
patients receiving adjuvant trastuzumab, the incidence of cardiac events in a “real world” population
is in the range of that reported in the pivotal clinical trials [9].
Beyond a 2.6% incidence of clinically evident congestive heart failure (Class II–IV according
to the New York Heart Association), about 8% of the patients experienced an asymptomatic, but
significant LVEF drop of >10% to below 50%. Interestingly, only 67% of these patients, at a median
follow-up of 5 years, had an LVEF recovery. Finally, the incidence of mild cardiac toxicity not leading
to discontinuation of trastuzumab was not reported (i.e., >10% but not to below 50%). In general, this
type of LVEF drop is not reported in clinical trials and real-world studies.
A large analysis with 13 years of follow-up recently addressed this often overlooked issue.
The authors focused on the implications of an early, asymptomatic LVEF drop on the subsequent
development of significant or symptomatic cardiac toxicity [10]. In 337 out of 787 patients, a 5% or
more LVEF loss from baseline occurring within the initial 3 months of trastuzumab treatment was
predictive of the development of either a significant, asymptomatic reduction in LVEF or of congestive
heart failure, which occurred in 5% and 2.3% of patients, respectively.
While this study points at early and small LVEF decreases as a predictor of “on-treatment” cardiac
dysfunction, the long-term consequences of early and asymptomatic LVEF loss that, by guidelines,
does not require trastuzumab interruption, are mostly unknown.
Our finding that LVEF after trastuzumab treatment is significantly lower than at the baseline is
consistent with the long-term data of the PHARE trial, investigating one year vs. 6 months of adjuvant
trastuzumab treatment [11]. At a 30-months follow-up cutoff, LVEF mean values, that had declined by
3.6% at the end of trastuzumab treatment, compared with baseline values, tended to recover, but for
almost a half of the patients, LVEF recovery was only partial. Still, the question remains “would failure
to recover to a pre-treatment LVEF value predispose patients to late cardiac events?” awaits a response.
Yet, if early LVEF drop predicts on-treatment cardiac events, in a woman who has completed adjuvant
trastuzumab, ageing and related conditions, use of adjuvant endocrine therapy and menopausal
changes may concur, together with a compromised myocardial function, to late cardiac effects.
Due to the importance of cardiac-related events associated with trastuzumab-based adjuvant
therapy, clinical trials have been conducted to assess the worth of chemoprevention with cardiac drugs
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in patients exposed to either anthracycline, trastuzumab or both in the adjuvant setting [12–17]. Of these,
three focused specifically on trastuzumab-related cardiac toxicity, which is pathogenetically different
from anthracycline-related cardiomyopathy and have been fully published [12,16,17]. Boekhout
and colleagues enrolled 210 women undergoing adjuvant trastuzumab-based therapy, who were
randomized to either placebo or the angiotensin-II receptor inhibitor candesartan. Study treatment
was started concomitantly with trastuzumab and continued until 26 weeks from trastuzumab
completion [12]. In this study, candesartan failed to show any effect on LVEF decrease or the
development of cardiac toxicity and found no correlation with cardiac biomarkers (NT-proBNP and
hs-TnT). The Manticore study was a three-arm, randomized study evaluating whether, compared
with placebo, perindopril, or bisoprolol given for the entire duration of trastuzumab therapy could
prevent trastuzumab-mediated cardiac remodelling, compared with placebo [16]. Although an effect
on avoiding LVEF losses was observed, neither bisoprolol nor perindopril could prevent cardiac
remodeling. In a larger, randomized, double-blind, phase III study, Gauglin and colleagues evaluated
whether lisinopril or carvedilol could reduce cardiac events, compared with placebo [17]. While in the
overall population the rate of cardiac toxicity and the cardiotoxicity-free interval were comparable in
the three arms, patients who had been previously exposed to anthracycline and treated with either
lisinopril or carvedilol experienced longer cardiotoxicity-free interval. Taken together, these studies do
not strongly support the systematic use of cardiac medication in all candidates to trastuzumab-based
adjuvant therapy.
Differently from the studies mentioned above, we sought to target early and mild asymptomatic
LVEF reductions, which occurred in 16% of the patients. We believe that our findings concur to
confirm a role for cardiac drugs to be used proactively in patients whose LVEF values show a mild
decline after the start of trastuzumab-based therapy. We must, however, acknowledge some limitations
of our study, which was a relatively small, non-randomized trial enrolling patients who were not
already on treatment with the classes of cardiac drugs that we used. Consequently, this may have
influenced the low rate of moderate or severe cardiac dysfunction that we observed, with only one
patient discontinuing treatment and no patient developing an LVEF drop >10% to below 50%. Yet,
a relative contribution of early intervention with cardiac drugs to this low rate clinically significant
events can be assumed, also considering the results of the other available clinical trials. Furthermore,
the lack of a randomized design does not allow us to conclude with confidence that the extent of LVEF
recovery after nadir values was due to cardiac drugs. Indeed, an improvement from nadir values was
also seen in patients who did not develop the cardiac event of interest in the absence of drugs.
On the other hand, our study also has some strengths; for example, all LVEF evaluations were
performed by the same cardiologists (A.B.), using the same instrument and the same protocol. Indeed,
having chosen to focus on mild LVEF changes, interobserver variability could be an issue in multicentric
studies [18]. Furthermore, all patients were managed at our breast clinic, ensuring consistency of
treatment procedures.
4. Materials and Methods
4.1. Study Population
CARDIORETE (EudraCT number 2011-002207-15) is a nonrandomized, open-label, interventional,
single group cardiac safety study conducted in full accordance with Good Clinical Practice
guidelines/Declaration of Helsinki.
All consecutive women with non-metastatic breast cancer eligible for trastuzumab-based adjuvant
therapy at our Institution from 1 May 2012 to 31 September 2016 were screened for this protocol.
The main inclusion criteria were age ≥18 years, newly diagnosed, HER2-overexpressing,
non-metastatic breast cancer, planned adjuvant treatment with trastuzumab, renal, hepatic and
bone functions permissive for planned treatment, and ability to provide informed consent.
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Exclusion criteria included baseline LVEF < 55%, active cardiological comorbidity, contraindication
to, or current treatment with, ACEi or BB and uncontrolled, non-cardiac concomitant diseases. Patients
were planned to receive trastuzumab intravenously, according to international protocols, for one year.
No patient received pertuzumab added to trastuzumab, because this drug is not funded in Italy for
patients with early, HER2-positive breast cancer.
The reference Ethics Committee approved the protocol (Comitato Etico Interaziendale Ospedale
San Luigi Gonzaga, Regione Gonzole 10, 10043, Orbassano, Italy, determination number 147/2011 of
17/Oct/2011) and written informed consent was obtained from all patients before the initiation of neo-
or adjuvant therapy.
4.2. Study Objectives
The primary objective of this study was to evaluate the effect of early intervention with ACE
inhibitors and beta-blockers in women developing mild cardiac toxicity (MCT), defined as an
asymptomatic absolute decrease in LVEF of ≥ 10 units from baseline to no less than 50%. In
these circumstances, widely adopted algorithms suggest trastuzumab continuation and no indication
of pharmacological treatments [4].
Secondary objectives included the study of risk factors for MCT in a population of patients
undergoing adjuvant, trastuzumab-based therapy, including baseline levels of plasma BNP (b-type
natriuretic peptide) and TnI. Included in our original objectives, but not reported in this paper were;
(1) the evaluation of fluctuations of BNP and TnI during treatment, and (2) the study of baseline
ultrasonographic parameters that could predict MCT. These two latter objectives will be reported in a
further manuscript.
4.3. Study Procedures
LVEF measurement by echocardiography was performed at baseline (before chemotherapy and/or
trastuzumab administration), every 3 months during trastuzumab therapy and at 6 and 12 months
after the completion of the scheduled treatment. Patients with MCT were identified by the cardiologist
during LVEF examination, placed on study drugs and followed up every two weeks during drugs
up-titration. Once reached target drug doses, patients were referred to the the cardiologist outside the
scheduled LVEF assessments only if clinically indicated. In patients lost to follow-up or who died for
breast cancer, the last evaluation was considered as the final measurement.
In patients developing MCT, treatment with enalapril 2.5 mg bid and carvedilol 3.75 mg bid was
initiated and up-titrated to the maximum established dose (10 mg bid for the enalapril and 6.25 mg bid
of carvedilol). Study drugs were administered during adjuvant trastuzumab treatment and continued
for three weeks after the last trastuzumab infusion, provided that patients were still asymptomatic and
with LVEF within normal Institutional limits (≥55%). Otherwise, cardiac drugs could be continued if
clinically indicated. Since there is no recommendation to treat with ACE inhibitors and beta-blockers
patients with mild cardiac toxicity as it was defined in our paper, we decided to limit the administration
of study drugs to the completion of adjuvant trastuzumab. Patients with significant cardiotoxicity
were treated according to guidelines, including trastuzumab temporary or definitive discontinuation
and pharmacological interventions.
4.4. Cardiac Biomarker Evaluation
Plasma BNP (b-type natriuretic peptide) and Troponin I (TnI) concentration were determined
before chemotherapy treatment start, before trastuzumab start, and at each cardiologic check during
and after the completion of the therapy. Levels of BNP were determined by the Triage BNP test
(Beckman Coulter, Inc. Brea, CA, USA) using the Beckman Access DxI 800 platform. The upper limit
of normal was 100 pg/mL. Levels of TnI were determined by the Access AccuTnI immunometric assay
(Beckman Coulter) using the Beckman DxI 800 platform. The upper limit of normal was 0.05 ng/mL.
Determinations were carried on in our laboratory according to the manufacturer’s instructions.
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In the current paper, we analyzed only baseline values as potential predictors of cardiac events.
4.5. Statistical Methods
In patients receiving study drugs, the primary end-point was LVEF recovery, which was defined
as a post-trastuzumab LVEF returning to no less than −5 percentage points of the baseline value.
The study was initially planned to be multi-institutional, to accrue 200 patients and to include
a historical comparison cohort. We started accrual at our Institution but faced budget problems
and difficulties in standardizing LVEF protocol at the other participating Institutions to minimize
inter-operator variability. We, therefore, decided to proceed as a single Institution. Due to resizing,
the aim of this study is exploratory, and no formal sample size calculation has been performed. The
proportion of patients developing MCT is described, together with its 95% Confidence Interval (C.I.).
Proportions were compared by the Chi-square test. Comparison between inter-patient and intrapatient
LVEF, TN and BNP values at the baseline and at various time-points during treatment were performed
by the Mann-Whitney U test and by the Wilcoxon rank test for paired samples, respectively. The Kaplan
Meier method was used to describe the probability of developing MCT during treatment. Finally, uni-
and multivariable logistic regression analysis was used to identify predictors of the MCT. All tests
were performed by the IBM SPSS version 22 package (Chicago, IL, USA). Statistical significance was
set at p < 0.05.
5. Conclusions
Randomized trials with cardiac drugs enrolling candidates to adjuvant trastuzumab-based therapy
have so far provided inconclusive results. Current guidelines still recommend treating symptomatic
patients only, or those that need trastuzumab withholding because of declining LVEF. Considering
results, strengths and limitations, our data hint at a potential utility of targeted intervention with
cardiac drugs in cases of asymptomatic, mild LVEF reductions. Furthermore, our data concur with
other observations to define the need for anthracycline-free, trastuzumab-based regimens as a strategy
to minimize early and late cardiac toxicity and to allow full adherence to trastuzumab treatment [19].
Being generated in the context of a mono-Institutional, non-randomized study, we believe that our
data should be confirmed in a randomized clinical trial before their adoption in the clinical practice.
Furthermore, the question of whether LVEF decline observed comparing pre- and post- trastuzumab
values has long-term implications remains still open and relevant. To get further insights into this
issue, we are planning a long-term evaluation of LVEF values in patients enrolled in this study and
undergoing regular follow-up visits at our Institution.
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